1. Journal of Geriatric Oncology
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies 
Parameswaran Hari, Dorothy Romanus, Katarina Luptakova, Marlo Blazer, Candice Yong, Aditya Raju, Eileen Farrelly, Richard Labotka, Vicki A. Morrison 
Journal of Geriatric Oncology 
DOI: /j.jgo
Copyright © Terms and Conditions

2. Fig. 1
Cumulative incidence of comorbid RI and CVD from first- to second-line therapy in patients with RRMMa.
aCo-morbidities for 1LT initiation are relative to the 12months prior to 1LT to initiation of 1LT; comorbidities for 2LT initiation are relative to the 12months prior to 1LT initiation through initiation of 2LT.
Key: 1LT – first-line therapy; 2LT – second-line therapy; CVD – cardiovascular disease; RI – renal insufficiency; RRMM – relapsed/refractory multiple myeloma.
Journal of Geriatric Oncology DOI: ( /j.jgo )
Copyright © Terms and Conditions

3. Fig. 2
Time to next treatmenta (A) and overall survival (B) by line of therapy.
aTTNT was the prespecified surrogate indicator for PFS.
Key: 2LT – second-line therapy; 3LT – third-line therapy; LOT – line of therapy; OS – overall survival; TTNT – time to next treatment.
Journal of Geriatric Oncology DOI: ( /j.jgo )
Copyright © Terms and Conditions

4. Fig. 3
Predicted adjusted time to next treatmenta from initiation of second-line therapy (A) by ageb, and (B) by the presence of either RI, CVD, or bothc
aTTNT was the prespecified surrogate indicator for PFS.
bAdjusted for renal insufficiency, CVD, gender, cytogenetic risk, type of 2LT (triplet vs not), race, year of diagnosis (continuous), type of 1LT (PI, IMID, PI/IMID, other), front-line SCT history, and geographic region.
cAdjusted for age (<75years vs ≥75 years), gender, cytogenetic risk, type of 2LT (triplet vs not), race, year of diagnosis (continuous), type of 1LT (PI, IMID, PI/IMID, other), front-line SCT history, and geographic region.
Key: 1LT – first-line therapy; 2LT – second-line therapy; CI – confidence interval; CVD – cardiovascular disease; HR – hazard ratio; RI – renal insufficiency; TTNT – time to next treatment.
Journal of Geriatric Oncology DOI: ( /j.jgo )
Copyright © Terms and Conditions

5. Fig. 4
Predicted adjusted overall survival from initiation of second-line therapy (A) by agea, and (B) by the presence of either RI, CVD, or bothb.
aAdjusted for renal insufficiency, CVD, gender, cytogenetic risk, type of 2LT (triplet vs not), race, year of diagnosis (continuous), type of 1LT (PI, IMID, PI/IMID, other), front-line SCT history, and geographic region.
bAdjusted for age (<75years vs ≥75 years), gender, cytogenetic risk, type of 2LT (triplet vs not), race, year of diagnosis (continuous), type of 1LT (PI, IMID, PI/IMID, other), front-line SCT history, and geographic region.
Key: 1LT – first-line therapy; 2LT – second-line therapy; CI – confidence interval; CVD – cardiovascular disease; HR – hazard ratio; OS – overall survival; RI – renal insufficiency.
Journal of Geriatric Oncology DOI: ( /j.jgo )
Copyright © Terms and Conditions